BioTelemetry Partners for NASH/NAFLD Trials

Oct 25, 2017
By Applied Clinical Trials Editors

BioTelemetry, provider of wireless medical technology announced its global imaging and cardiac core lab, has formed an alliance with AMRA to address imaging of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) clinical trials. AMRA’s body composition analysis service has introduced a new paradigm where rapid, six-minute whole body MRI scans are transformed into precise, three dimensional-volumetric fat and muscle measurements. This standardized, automated method eliminates reader variability and reduces processing costs.

Read the full release here.

 

 

native1_300x100
lorem ipsum